Review
Patient Referral
In: The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 44.
.
Affiliations
- PMID: 36122079
- Bookshelf ID: NBK584185
- DOI: 10.1007/978-3-030-94353-0_44
Item in Clipboard
Review
Patient Referral
Excerpt
Early and efficient patient referral is a critical step in the ability of potential candidates to access CAR-T therapy. Despite improvements in centre qualification and availability, regulatory and reimbursement frameworks, and addressing the educational needs of the various members of the health care team, referring haematologists and oncologists identify major barriers to prescribing CAR-T therapy, including cumbersome logistics, high cost and toxicity, and clinical challenges, such as deterioration of the patient prior to CAR-T administration and the need for bridging chemotherapy while awaiting manufacturing.
Copyright 2022, The Author(s).
Sections
References
-
- Chavarría T. Real-world regulatory issues in the implementation of advanced therapies. Multistakeholder forum at 47th EBMT annual meeting. 2021. Available at www.ebmt.org
-
- Gajra A, Jeune-Smith Y, Kish J, Yeh T-C, Hime S, Feinberg B. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma. Immunotherapy. 2020;12(10):725–32. https://doi.org/10.2217/imt-2020-0118. - DOI - PubMed
-
- Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist. 1996;21:608–17. https://doi.org/10.1634/theoncologist.2015-0421. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
